Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKinsey
Harvard Business School
Merck
Moodys
Colorcon
AstraZeneca

Last Updated: April 5, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Orteronel


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Orteronel?

Orteronel is an investigational drug.

There have been 17 clinical trials for Orteronel. The most recent clinical trial was a Phase 3 trial, which was initiated on May 1st 2012.

The most common disease conditions in clinical trials are Prostatic Neoplasms, Breast Neoplasms, and Ovarian Neoplasms. The leading clinical trial sponsors are Millennium Pharmaceuticals, Inc., National Cancer Institute (NCI), and University of Wisconsin, Madison.

There are five US patents protecting this investigational drug and forty-seven international patents.

Recent Clinical Trials for Orteronel
TitleSponsorPhase
AR-inhibitor Bicalutamide in Treating Patients With TNBCJiangsu Province Hospital of Traditional Chinese MedicinePhase 2
AR-inhibitor Bicalutamide in Treating Patients With TNBCNanning Second People's HospitalPhase 2
AR-inhibitor Bicalutamide in Treating Patients With TNBCThe First People's Hospital of LianyungangPhase 2

See all Orteronel clinical trials

Clinical Trial Summary for Orteronel

Top disease conditions for Orteronel
Top clinical trial sponsors for Orteronel

See all Orteronel clinical trials

US Patents for Orteronel

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Orteronel   Start Trial Modulation of androgen receptor expression ISIS Pharmaceuticals Inc. (Carlsbad, CA)   Start Trial
Orteronel   Start Trial Androgen receptor down-regulating agents and uses thereof University of Maryland, Baltimore (Baltimore, MD)   Start Trial
Orteronel   Start Trial Modulation of androgen receptor expression Ionis Pharmaceuticals, Inc. (Carlsbad, CA)   Start Trial
Orteronel   Start Trial Inhibitors of CYP17A1 UNIVERSITY OF KANSAS (Lawrence, KS)   Start Trial
Orteronel   Start Trial Androgen receptor down-regulating agents and uses thereof University of Maryland, Baltimore (Baltimore, MD) University of Maryland Eastern Shore (Princess Anne, MD) Thomas Jefferson University (Philadelphia, PA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Orteronel

Drugname Country Document Number Estimated Expiration Related US Patent
Orteronel Argentina 092982 2032-10-11   Start Trial
Orteronel Australia 2013329070 2032-10-11   Start Trial
Orteronel Australia 2017200759 2032-10-11   Start Trial
Orteronel Brazil 112015007878 2032-10-11   Start Trial
Orteronel Canada 2887867 2032-10-11   Start Trial
Orteronel Chile 2015000901 2032-10-11   Start Trial
Orteronel China 104703610 2032-10-11   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Johnson and Johnson
Dow
Harvard Business School
McKinsey
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.